- Home
- NCTY vs ANVS Comparison
NCTY vs ANVS Comparison
Compare NCTY & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCTY | ANVS |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.2M | 69.1M |
| IPO Year | 2004 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NCTY | ANVS |
|---|---|---|
| Price | $5.20 | $1.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 28.3K | ★ 1.2M |
| Earning Date | 03-27-2015 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.00 | $1.54 |
| 52 Week High | $11.60 | $5.50 |
Technical Indicators
Market Signals| Indicator | NCTY | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 43.64 |
| Support Level | $5.05 | $1.79 |
| Resistance Level | $5.91 | $2.57 |
| Average True Range (ATR) | 0.39 | 0.17 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 6.63 | 24.29 |
Price Performance
Historical ComparisonAbout NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Online game services, out of which Crypto mining business derives maximum revenue.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.